Intelligence Thumbnail

I/O BioMAP – Immuno-Oncology Biomarker Analysis Platform

The DeciBio Immuno-Oncology Biomarker Analysis Platform (I/O BioMAP) is a dynamic, interactive database of biomarkers for cancer immunotherapies in clinical trials.  This database aggregates information about immuno-oncology biomarkers from clinical trials, including data about assay technology, sample type, biomarker purpose, trial sponsor, and many other parameters.  The tool is updated with data from new trials at least quarterly to provide the most comprehensive and up-to-date picture of the immuno-oncology biomarker landscape possible. The I/O BioMAP can also be customized to incorporate proprietary clinical trial datasets.

 

  • Author: Andrew Aijian
  • Date: Jul, 2017
Request Pricing

Product Workflow

 

Identify I/O Trials

Extract Information

Visualize Information
We conduct an extensive keyword analysis to identify open or active biomarker-containing I/O clinical trials within clinicaltrials.govWe use a combination of automated and manual data extraction techniques, leveraging a team of experienced cancer researchers, to capture as much biomarker information as possible from the trialsThe data is visualized and segmented across several dashboards to enable rapid exploratory trend analysis

Key Use-Cases


Pharma Companies

• Stay up to speed on competitor biomarker strategies, clinical trial activity, technology utilization, and combination therapy strategies
• Identify potential gaps in biomarker strategy
• Identify new potential markers being explored for your drugs by academic and research institutions

CROs

• Target potential pharma customers
• Anticipate the assays, technologies, and sample type requirements potential pharma partners will need for cancer immunotherapy trials
• Prioritize immuno-oncology service offerings

Clinical Labs

• Identify potential up-and-coming assays to offer to your patients and customers
• Prioritize your assay development roadmap
• Identify tools and technologies that may be needed for future diagnostics offerings

Tools and Diagnostics Companies

• Identify markers that might become clinically relevant diagnostic opportunities
• Discover genes / proteins to add to your existing panels
• Prioritize your assay development roadmap
• Identify potential research and/or commercial partners for CDx development
• Inform technology strategy

 

Dashboard Demo

The BioMAP is an interactive database.  The videos below shows how users can segment and filter the biomarker data in a dynamic and granular fashion.

Check out our blog post here for some highlights and takeaways from our analysis of the BioMAP data.

Licensing and Pricing

Access to the I/O BioMAP is provided as a global license, allowing anyone from a customer organization to access the tool.  The tool is made available on the cloud via Tableau Online; a local version of the Tableau file can also be provided for those with access to Tableau and/or the Tableau reader.  Pricing for the I/O BioMAP ranges from $2,500 – $45,000 annually, depending on the organization size, the number of dashboards desired, and the desired update frequency.  Please click on the “Request Pricing” button above to see the pricing options for your organization.

 

Sample Insights

IO-Biomap

Immuno-Oncology Biomarker of the Week

IO-Biomap1

Diagnostic Biomarkers for Cancer Immunotherapy – Updated Jan.2017

IO-Biomap

Immuno-Oncology Summit Takeaways – Immuno-Oncology Biomarkers 2.0

 

Lead Author | Andrew Aijian, PhD

At DeciBio, Dr. Aijian has worked on several engagements, covering all types of therapeutic areas and diagnostic technologies. In these projects, Andrew has lead extensive secondary and primary research campaigns, developed bottom-up and top-down market models, constructed NPV forecasts, and evaluated customer feedback and market potential for client product profiles.

Schedule a 30 minutes report demo with Andrew today!

    Footer Background Image

    How can we help?

    Avoid blind spots in your market. Get the insights you need to accelerate innovation.

    Contact Us